Cencora

(New York Stock Exchange)
Back to all articles
Bullish +65

Cencora agrees to USD 2.4 billion deal as Cencora stock costs EUR 296.75

Acquisition Earnings report AI-generated analysis

πŸ“ˆ Cencora agreed to acquire American Oncology Network for an enterprise value of USD 2.4 billion.

πŸ’° The deal includes USD 2.3 billion at closing plus contingent value rights of up to USD 100 million.

πŸ₯ American Oncology Network operates over 350 oncology providers across 21 states.

πŸ“Š Cencora raised its fiscal 2026 adjusted EPS floor to USD 17.90 following the deal announcement.

πŸš€ Management expects the acquisition to add to adjusted diluted EPS in the second year after closing.

πŸ’Ή Q3 2026 results showed adjusted EPS of USD 4.48, beating the consensus estimate of USD 4.35.

πŸ“ˆ Revenue for fiscal third quarter reached USD 84.75 billion.

πŸ—“οΈ Fiscal fourth-quarter results are scheduled to be released before the NYSE opens on November 4, 2026.

🏒 Cencora already owns a 4 percent stake in American Oncology Network prior to this acquisition.

βš–οΈ The transaction remains subject to regulatory clearances and shareholder approval.

Bullish Signals
  • Cencora agreed to a USD 2.4 billion oncology deal to acquire American Oncology Network, expanding its provider footprint across 21 states.
  • Management raised fiscal 2026 adjusted EPS guidance to USD 17.90, placing the target at the high end of the previous range.
  • The company expects the acquisition to add to adjusted diluted earnings per share in the second year after closing.
  • Cencora beat Q3 consensus estimates with adjusted EPS of USD 4.48 versus a USD 4.35 expectation.
  • Revenue for the fiscal third quarter reached USD 84.75 billion, demonstrating strong top-line performance.
Full Analysis
Cencora Inc. has agreed to acquire American Oncology Network for an enterprise value of USD 2.4 billion, marking a significant expansion in its oncology portfolio. The deal structure includes USD 2.3 billion in cash at closing and contingent value rights of up to USD 100 million, with Cencora expecting to pay approximately USD 1.7 billion if eligible shareholders retain a 25 percent stake via an equity rollover. This acquisition targets American Oncology Network, which operates more than 350 oncology providers across 21 states. Cencora already holds a 4 percent stake in the network prior to this transaction. The agreement is currently subject to necessary regulatory clearances and shareholder approval before it can be finalized. Following the announcement of the oncology deal, Cencora raised its fiscal 2026 adjusted earnings per share (EPS) floor to USD 17.90, positioning itself at the high end of its previously guided range of USD 17.75 to USD 17.95. Management expects the acquisition to contribute positively to adjusted diluted EPS in the second year following the closing of the transaction. Cencora recently reported strong fiscal third-quarter results with adjusted EPS of USD 4.48, beating the consensus estimate of USD 4.35, and revenue reaching USD 84.75 billion. The company plans to release its fiscal fourth-quarter results before the New York Stock Exchange opens on November 4, 2026. Cencora's stock is primarily listed on the NYSE with a market capitalization of USD 63.2 billion as of late October 2026. While trading at EUR 296.75 in European markets, the company maintains a strong presence in the healthcare distribution sector.